refractory Lymphoblastic Leukemia, Acute, Childhood (DBCOND0142191)

Identifiers

Synonyms

Refractory Childhood Acute Lymphoblastic Leukemia

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Teniposide	A cytotoxic drug used as an adjunct for chemotherapy induction in the treatment of refractory childhood acute lymphoblastic leukemia.	DNA topoisomerase 2-alphatarget Cytochrome P450 2C19enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A4enzyme ATP-binding cassette sub-family C member 6transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A5enzyme DNA topoisomerase 2-betatarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01858740	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	Fludarabine Methopterin Methotrexate Tacrolimus Thiotepa Tromethamine	treatment	2	completed
NCT05857969	Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling	No drug interventions	Not Available	Not Available	recruiting
NCT03860376	Ex Vivo Drug Sensitivity Testing and Mutation Profiling	No drug interventions	Not Available	Not Available	completed
NCT02819804	Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Dasatinib Nivolumab	treatment	1	terminated
NCT03289455	CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)	AUTO3	treatment	1 / 2	completed